Stéphane Bancel
Stéphane Bancel has served as Moderna's Chief Executive Officer since October 2011, playing a pivotal role in the company's growth and its groundbreaking work in mRNA technology. Under his leadership, Moderna developed a COVID-19 vaccine and is expanding its portfolio to include other vaccines and therapeutics. His strategic vision has been instrumental in driving Moderna's mission to revolutionize medicine and establish the company as a leader in biotechnology.
Career Milestones
- Stéphane Bancel became CEO of Moderna in 2011, transforming it into a leading biotechnology company.
- He led the rapid development and global rollout of Moderna's COVID-19 vaccine, Spikevax, in 2020, significantly impacting global public health.
- In 2021, Fortune magazine recognized him as a top Businessperson of the Year for his leadership and innovation.
- He was nominated Chevalier of the Legion d'honneur in 2022, France's highest recognition, for his leadership during the pandemic.
- In 2024, Bancel was elected to the U.S. National Academy of Engineering for his contributions to pharmaceutical product development. These achievements underscore his commitment to advancing mRNA technology for global health.
About Moderna
Moderna, founded in 2010, is a biotechnology company specializing in mRNA therapeutics and vaccines. They help patients by developing transformative medicines for infectious diseases, cancer, and rare genetic disorders. Their core feature is their proprietary mRNA platform, enabling rapid development of vaccines and therapies. Benefits include addressing global health challenges and improving patient outcomes.